The clinical role and cost-effectiveness of long-acting antiretroviral therapy.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Infectious Diseases

• Publication date

  2015-04-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1093/cid/ciu1159PMID 25583979PMCID PMC4366583
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Compartmental Pharmacokinetic Evaluation of Long‐Acting Rilpivirine in HIV‐Negative Volunteers for Pre‐Exposure Prophylaxis

  2014cited by this paper
• Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States

  2013cited by this paper
• Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor

  2013cited by this paper
• Heterogeneity Among Studies in Rates of Decline of Antiretroviral Therapy Adherence Over Time: Results From the Multisite Adherence Collaboration on HIV 14 Study

  2013cited by this paper
• Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744

  2013cited by this paper
• Cost-Effectiveness Analysis of Ugt1A1 Genetic Testing to Inform Antiretroviral Prescribing in HIV Disease

  2013cited by this paper
• Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America

  2012cited by this paper
• Adherence to Antiretroviral Treatment and Correlation with Risk of Hospitalization among Commercially Insured HIV Patients in the United States

  2012cited by this paper
• Retention in a public healthcare system with free access to treatment: a Danish nationwide HIV cohort study

  2012cited by this paper
• Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.

  2012cited by this paper
• Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice

  2012cited by this paper
• Racial/Ethnic Disparities in ART Adherence in the United States: Findings From the MACH14 Study

  2012cited by this paper
• Establishment, Retention, and Loss to Follow-Up in Outpatient HIV Care

  2012cited by this paper
• Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.

  2011cited by this paper
• Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

  2011cited by this paper
• Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

  2011cited by this paper
• The critical need for alternative antiretroviral formulations, and obstacles to their development.

  2011cited by this paper
• Lack of sustained improvement in adherence or viral load following a directly observed antiretroviral therapy intervention.

  2011cited by this paper
• Antiretroviral Therapy Adherence, Medication Use, and Health Care Costs During 3 Years of a Community Pharmacy Medication Therapy Management Program for Medi-Cal Beneficiaries with HIV/AIDS

  2011cited by this paper
• Association Between Medication Possession Ratio, Virologic Failure and Drug Resistance in HIV-1–Infected Adults on Antiretroviral Therapy in Côte d'Ivoire

  2011cited by this paper
• Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation

  2010cited by this paper
• The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals

  2010cited by this paper
• Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

  2010cited by this paper
• Late presentation for human immunodeficiency virus care in the United States and Canada.

  2010cited by this paper
• Assessing agreement in the timing of treatment initiation determined by repeated measurements of novel versus gold standard technologies with application to the monitoring of CD4 counts in HIV‐infected patients

  2010cited by this paper
• A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people

  2010cited by this paper
• Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.

  2009cited by this paper
• The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over Time

  2009cited by this paper
• Not All Missed Doses Are the Same: Sustained NNRTI Treatment Interruptions Predict HIV Rebound at Low-to-Moderate Adherence Levels

  2008cited by this paper
• The survival benefits of AIDS treatment in the United States.

  2006cited by this paper
• Value of Medical Innovation in the United States: 1960-2000

  2006cited by this paper
• The value of medical spending in the United States.

  2006cited by this paper
• The value of medical spending in the United States, 1960-2000.

  2006cited by this paper
• Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 109 cells/L

  2003cited by this paper
• The cost effectiveness of combination antiretroviral therapy for HIV disease.

  2001cited by this paper
• Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000

  1998cited by this paper
• Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

  1996cited by this paper

• Preferences for long-acting antiretroviral therapy among people with HIV: A systematic review of discrete choice experiments.

  2026cites this paper
• Prioritizing long-acting injectable antiretroviral therapy among key populations: Perceptions of persons living with HIV who inject drugs, ART clinic staff, and policymakers in Vietnam

  2025cites this paper
• Cost-effective pricing of long-acting injectable HIV pre-exposure prophylaxis for adolescent girls and young women in South Africa: a model-based analysis

  2025cites this paper
• Impact of increased uptake of long-acting injectable antiretroviral therapy on HIV incidence and viral suppression in the United States under 2021 FDA guidelines

  2025cites this paper
• Cost-effectiveness of long-acting cabotegravir/rilpivirine for people with HIV and adherence challenges at the Ward 86 clinic: an intermediate outcome analysis

  2025cites this paper
• Projected Life Expectancy for Adolescents With HIV in the US

  2024cites this paper
• Long-Acting Cabotegravir Plus Rilpivirine in People with HIV with Adherence Challenges and Viremia: Current Data and Future Directions.

  2024cites this paper
• Access to a novel first-line single-tablet HIV antiretroviral regimen in Affordable Care Act Marketplace plans, 2018–2020

  2023cites this paper
• Projected Life Expectancy Gains From Improvements in HIV Care in Black and White Men Who Have Sex With Men

  2023cites this paper
• Considerations for long-acting antiretroviral therapy in older persons with HIV

  2023cites this paper
• Projected Benefits of Long-Acting Antiretroviral Therapy in Nonsuppressed People With Human Immunodeficiency Virus Experiencing Adherence Barriers

  2023cites this paper
• Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain

  2023cites this paper
• Experiences and practices of key research team members in obtaining informed consent for pharmacogenetic research among people living with HIV: a qualitative study

  2022cites this paper
• A growing number of men who have sex with men aging with HIV (2021-2031): a comparison of two microsimulation models.

  2022cites this paper
• Experiences and practices of key research team members in obtaining informed consent for pharmacogenetic research among people living with HIV: a qualitative study

  2022cites this paper
• Clinical implementation of long-acting antiretroviral treatment in high-income countries: challenges and advantages

  2022cites this paper
• Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States

  2022cites this paper
• The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?

  2021cites this paper
• Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study

  2021influential citation
• Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States.

  2020cites this paper
• Modeling the health impact and cost threshold of long-acting ART for adolescents and young adults in Kenya

  2020cites this paper
• Feasibility of Implementing Long-Acting Injectable Antiretroviral Therapy to Treat HIV: A Survey of Health Providers from the 13 Countries Participating in the ATLAS-2M Trial

  2020cites this paper
• Cost-Effectiveness of antiretroviral therapy: A systematic review

  2020cites this paper
• Pharmacogenomics and Infectious Diseases in Africa

  2019cites this paper
• Cost-effectiveness of a Medical Care Coordination Program for People With HIV in Los Angeles County

  2019cites this paper
• Theranostics for Antiretroviral Biodistribution and Pharmacokinetics

  2019cites this paper
• Clinical impact and cost-effectiveness of genotype testing at HIV diagnosis in the United States.

  2019cites this paper
• Current and future priorities for the development of optimal HIV drugs

  2019cites this paper
• Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities.

  2018cites this paper
• Emerging reverse transcriptase inhibitors for HIV-1 infection

  2018cites this paper
• Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States

  2017cites this paper
• Long-Acting Antiretrovirals: Where Are We now?

  2017cites this paper
• Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States

  2017cites this paper
• The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States

  2017cites this paper
• High self-reported non-adherence to antiretroviral therapy amongst adolescents living with HIV in Malawi: barriers and associated factors

  2017cites this paper
• Pharmacogenomic implications of the evolutionary history of infectious diseases in Africa

  2016cites this paper
• Novel gene and cellular therapy approaches for treating HIV.

  2016cites this paper
• Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study.

  2016cites this paper
• Survival benefits of antiretroviral therapy in Brazil: a model-based analysis

  2016cites this paper
• Past, Present, and Future Drug Delivery Systems for Antiretrovirals.

  2016cites this paper
• Tenofovir alafenamide for HIV: time to switch?

  2016cites this paper
• The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.

  2016cites this paper
• Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).

  2016cites this paper
• Creation of a Long-Acting Nanoformulated 2′,3′-Dideoxy-3′-Thiacytidine

  2016cites this paper
• Implementation challenges for long-acting antivirals as treatment

  2015cites this paper
• Current state and limitations of daily oral therapy for treatment

  2015cites this paper
• Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.

  2015cites this paper
• Modeling the clinical and economic implications of obesity using microsimulation

  2015cites this paper
• The Impact of the 2013 WHO Antiretroviral Therapy Guidelines on the Feasibility of HIV Population Prevention Trials

  2014cites this paper